PMID- 37620427 OWN - NLM STAT- MEDLINE DCOM- 20240221 LR - 20240222 IS - 1476-5608 (Electronic) IS - 1365-7852 (Linking) VI - 27 IP - 1 DP - 2024 Mar TI - Real-world four-year functional and surgical outcomes of Rezum therapy in younger versus elderly men. PG - 109-115 LID - 10.1038/s41391-023-00703-0 [doi] AB - BACKGROUND: Management of urinary symptoms in elderly patients with benign prostatic hyperplasia (BPH) is complex given challenges with medications and invasive surgeries. Rezum, a minimally invasive water vapor therapy, is an emerging alternative. We compare real-world Rezum outcomes between young and elderly patients over 4 years. METHODS: We retrospectively analyzed a multiethnic population treated with Rezum at a single center between 2017-2019. Patients were stratified into young (<65 years) or elderly (>/=65 years) cohorts. International Prostate Symptom Score (IPSS), Quality of Life (QoL), maximum urinary flow rate (Qmax), decisional regret scores, and adverse events (AEs) were assessed at baseline, 1-, 3-, 6-, 12-, and/or 48-months. Descriptive statistics were compared using t-tests, Chi-squared, or Mann-Whitney U tests. Changes in outcomes were assessed using Wilcoxon signed-rank tests, stratified by age. RESULTS: 256 patients - 146 (57%) young and 110 (43%) elderly - were included. The majority were Asian (33.2%) or non-Hispanic Black (28.9%). Significant improvements were observed in the combined cohort at 4-years in IPSS, QoL, and Qmax when compared to baseline (all p < 0.05). Between the age cohorts, there were no significant differences in IPSS, QoL, or Qmax at any follow-up. Within both cohorts, significant improvements in IPSS and QoL were found from baseline to all follow-ups. In the young cohort, Qmax was significantly improved from baseline to all follow-ups while in the elderly cohort, this was observed only at the 3-month follow-up. No significant differences in AEs or regret was found between cohorts. There was no significant difference in 4-year surgical retreatment rates between cohorts (elderly 4.0% vs young 4.4%, p = 0.86). CONCLUSIONS: There were no significant differences in IPSS, QoL, or AEs between elderly and younger men over 4 years following Rezum, suggesting comparable benefits and risks. Future research is warranted to clarify the impact of Rezum on Qmax in elderly men. CI - (c) 2023. The Author(s), under exclusive licence to Springer Nature Limited. FAU - Zhu, Michael AU - Zhu M AUID- ORCID: 0000-0001-5675-6403 AD - Albert Einstein College of Medicine, Bronx, NY, USA. Michael.Zhu@einsteinmed.edu. FAU - Babar, Mustufa AU - Babar M AUID- ORCID: 0000-0001-8490-2260 AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Hawks-Ladds, Noah AU - Hawks-Ladds N AUID- ORCID: 0009-0000-7826-7942 AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Tawfik, Marc-Mina AU - Tawfik MM AUID- ORCID: 0000-0002-7228-3682 AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Loloi, Justin AU - Loloi J AD - Department of Urology, Montefiore Medical Center, Bronx, NY, USA. FAU - Labagnara, Kevin AU - Labagnara K AUID- ORCID: 0000-0003-3275-1004 AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Sayed, Rahman AU - Sayed R AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Tang, Kevin AU - Tang K AUID- ORCID: 0000-0002-2908-1954 AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Salami, Azizou AU - Salami A AD - Albert Einstein College of Medicine, Bronx, NY, USA. FAU - Singh, Sandeep AU - Singh S AD - DSS Urology, Queens Village, New York, NY, USA. FAU - Singh, Jaskirat AU - Singh J AD - DSS Urology, Queens Village, New York, NY, USA. FAU - Ines, Matthew AU - Ines M AUID- ORCID: 0000-0003-0364-7398 AD - DSS Urology, Queens Village, New York, NY, USA. FAU - Iqbal, Nazifa AU - Iqbal N AD - DSS Urology, Queens Village, New York, NY, USA. FAU - Ciatto, Michael AU - Ciatto M AD - DSS Urology, Queens Village, New York, NY, USA. LA - eng PT - Journal Article DEP - 20230824 PL - England TA - Prostate Cancer Prostatic Dis JT - Prostate cancer and prostatic diseases JID - 9815755 SB - IM MH - Male MH - Humans MH - Aged MH - Quality of Life MH - *Lower Urinary Tract Symptoms/epidemiology MH - Retrospective Studies MH - Treatment Outcome MH - *Prostatic Neoplasms MH - *Prostatic Hyperplasia/surgery EDAT- 2023/08/25 00:41 MHDA- 2024/02/21 11:15 CRDT- 2023/08/24 23:27 PHST- 2023/04/19 00:00 [received] PHST- 2023/07/17 00:00 [accepted] PHST- 2023/07/10 00:00 [revised] PHST- 2024/02/21 11:15 [medline] PHST- 2023/08/25 00:41 [pubmed] PHST- 2023/08/24 23:27 [entrez] AID - 10.1038/s41391-023-00703-0 [pii] AID - 10.1038/s41391-023-00703-0 [doi] PST - ppublish SO - Prostate Cancer Prostatic Dis. 2024 Mar;27(1):109-115. doi: 10.1038/s41391-023-00703-0. Epub 2023 Aug 24.